Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorLaureate Institute for Brain Research, Inc.

About this trial

Approximately one third of individuals with Major Depressive Disorder (MDD) are considered treatment-resistant, subject to severe disability and risk of suicide, and exhibit symptoms anchored in abnormalities of Research Domain Criteria (RDoC) Negative Valence Systems behavioral processes. In the present study we plan to use low-intensity focused ultrasound in 120 persons with treatment-resistant MDD to modulate deep white matter tracts connecting the thalamus and different regions of the prefrontal cortex reversibly and non-invasively, with the aim of assigning a causal, mechanistic role to large scale brain circuits in the production of those critical behavioral abnormalities. A successful study will help to attain the precise definition of neuromodulation targets for this clinical population in utter need of help.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Persons 18-65 years old, with sex and ethnicity recruitment targets including a M:F proportion of 1:2 and White:Black:Hispanic:Native American proportion as close as possible to 8:2:2:1 to reflect the regional epidemiology of TRD (63% White American; 16% African American; 14% Hispanic of any race; 5% Native American),

DSM-5-TR diagnosis of MDD as confirmed by MINI structured interview followed by consultation with a board-certified psychiatrist,

two or more adequate (6 week) trials of antidepressants with different mechanisms,

evidence-based psychotherapy,

Disqualifiers

Clinical history of at least minor neurocognitive disorder of neurodegenerative origin,

PROMIS (Cognitive Function scale) score ≤40 (i.e., mean - 1SD), collected at baseline

clinical history of relevant structural pathology of the central nervous system, including Parkinson's disease, multiple sclerosis, and brain malignant neoplasia,

uncontrolled diabetes mellitus (as evidenced by a fasting glycemia ≥ 120 mg/dL or hemoglobin A1c ≥ 6.5%) or hypertension (as evidenced by two consecutive readings ≥ 140/90 mmHg) to ensure medical stability, collected at baseline

Trial design

Design model

Crossover

Treatments tested in this trial

  • Low-intensity focused ultrasound

    Other intervention

    80-second stimulus with an estimated tissue ISSPA=2.26 W/cm2, with (sham) or without (verum) interposition of Sorbothane film

Treatment groups

140 Participants
are divided into 3 treatment groups
Group A: Thalamo-Anterior Cingulate Cortex Tract LIFU SonicationExperimental treatment 1 intervention
Group B: Thalamo- Orbitofrontal Cortex Tract LIFU SonicationExperimental treatment 1 intervention
Group C: Sham LIFUSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

Post-Sonication Changes in Functional Connectivity

Changes in resting-state functional (fMRI) connectivity (FC) between thalamus and either Anterior Cingulate (ACC) or Orbitofrontal (OFC) cortices after LIFU or Sham stimulation.

Time frame
Pre- vs up to 30 minutes post-sonication or sham intervention.
2

Post-Sonication Changes in Reward and Repetitive Mentation

Changes in BOLD activation of either Anterior Cingulate (ACC) or Orbitofrontal Cortex (OFC) during Monetary Incentive Delay and Induced Rumination Tasks corresponding to changes in reward and repetitive thinking, respectively.

Time frame
Up to 30 minutes post-sonication vs sham intervention

Secondary outcomes

1

Post-Sonication Changes in Functional Connectivity and Anhedonic and Ruminative Symptoms

Changes in functional connectivity of thalamo-frontal and thalamo-anteiror cingulate regions and the correlation to changes in Snaith-Hamilton Pleasure Scale scores (minimum score: 0; maximum score: 14; lower scores mean better outcomes) and Brief State Rumination Inventory Scores (minimum value: 0; maximum value: 25; lower scores mean better outcomes) to evaluate anhedonic and ruminative symptoms respectively.

Time frame
Pre- vs up to 30 minutes post-sonication

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.